Keros Therapeutics Inc.

Keros Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of groundbreaking treatments for hematological and musculoskeletal disorders. The company's primary aim is to address unmet medical needs by advancing innovative therapies that target the transforming growth factor-beta (TGF-beta) family of proteins. These proteins play a critical role in the regulation of cellular growth and development, making them pivotal in treating a variety of severe diseases. Keros Therapeutics is deeply involved in research and development, with a strong pipeline of drug candidates aimed at conditions such as anemia and other blood-related disorders, as well as muscle diseases that impact patient mobility. By targeting these specific biological pathways, Keros is contributing significantly to the biopharmaceutical industry’s efforts in developing more effective and personalized medicine. The company's operations are an important part of the healthcare sector, striving to deliver breakthroughs that can enhance the quality of life for patients worldwide.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Jasbir S. Seehra Ph.D.

Employees

87

Headquarters

Lexington, MA, United States

Website

www.kerostx.com